Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 294 participants.
Also called NCT05350969
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 294 participants
- Sponsor
- Cardior Pharmaceuticals GmbH
- Registry
-
NCT05350969 -
2023-507569-24-00 -
2021-006040-27
-
- Other papers using this trial's data
- The microRNA inhibitor CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: a randomized phase 2 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Czechia, Germany, Greece, Hungary, Netherlands, Poland, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT05350969. Randomized; quadruple masking; primary purpose treatment. Start 2022-07-11 (actual); primary completion 2024-09-26 (actual). Results posted on 2026-08-26.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction
- Acronym
- HF-REVERT
- Condition
- Myocardial Infarction, Acute
- Condition
- Heart Failure, Left Sided
- Intervention (Drug)
- CDR132L
- Intervention (Drug)
- Placebo to CDR132L
- Lead sponsor
- Cardior Pharmaceuticals GmbH
Record details
- Record id
cardio:ct-nct05350969- Content hash
87e11027f3510424e198be302519256265be376dbce4b55b27ddb082a94fdf4c